Taishan District

Researchers are studying whether stopping long-acting glucagon-like peptide-1 receptor agonists GLP-1 RAs for one week before an esophagogastroduodenoscopy EGD improves the quality of stomach preparation and reduces the need to repeat the procedure. This phase 3 trial aims to determine if a one-week drug pause is a suitable recommendation prior to EGD for patients using GLP-1 RAs or tirzepatide. The study is randomized and double-blind, comparing patients who stop the drug for one week to those who do not. Participants are assigned to one of two groups one group stops GLP-1 RAs for one week before the EGD, and the other group continues their medication without interruption. The study assesses the cleanliness of the stomach lining during EGD using the PEACE scoring system, measured from enrollment to 30 days after treatment. Both groups receive standard care aside from the intervention to stop or continue GLP-1 RA use. During the trial, participants undergo routine outpatient visits, and their gastric preparation quality is evaluated during EGD. Researchers monitor the need for repeat EGD procedures and use the PEACE scoring system to assess stomach cleanliness. Participants must provide informed consent and meet eligibility criteria, including age and health status. The study completion is planned for June 2030, with primary outcome data collected up to 30 days post-treatment.

Researchers are evaluating how different stopping times of GLP-1 receptor agonists before a colonoscopy affect the quality of bowel preparation and the need for repeat procedures. These medications, used mainly for type 2 diabetes and weight management, slow stomach emptying and gut movement, which might reduce bowel cleansing effectiveness. The study aims to find the best discontinuation timing to improve colonoscopy results in patients using GLP-1 receptor agonists. Participants are randomly assigned to one of two groups stopping GLP-1 receptor agonists one week before colonoscopy or continuing these medications without stopping. Both groups undergo standard bowel cleansing with a polyethylene glycol regimen before the procedure. The study uses the Boston Bowel Preparation Scale BBPS to measure bowel cleanliness during colonoscopy and compares incomplete bowel preparation rates between groups. During the study, participants will have their bowel preparation quality assessed during colonoscopy and followed for 30 days afterward to monitor outcomes. Researchers will analyze the adequacy of bowel cleansing and the need for repeat colonoscopies. Participants must meet specific health criteria and are monitored for safety throughout the trial, which runs from June 2026 to June 2028.